Guanylin and uroguanylin are peptides that stimulate membrane guanylate cyclases (GC) and regulate intestinal and renal function via cGMP. Complementary DNAs were isolated encoding opossum preproguanylin and a 279-amino acid portion of a receptor-guanylate cyclase expressed in opossum kidney (OK) cells (GC-OK). The tissue expression of messenger RNA transcripts for these signaling molecules were then compared. Northern and/or reverse transciption-PCR assays revealed that guanylin, uroguanylin, and GC-OK messenger RNAs are expressed in tissues within the digestive, renal, central nervous, reproductive, and lymphoid organ systems. Receptor autoradiography localized the receptors for uroguanylin and guanylin to renal proximal tubules and seminiferous tubules of testis. Synthetic guanylin and uroguanylin peptides activated the receptor-GCs in opossum kidney cortex and in cultured OK cells eliciting increased intracellular cGMP. Expression of agonist and receptor-GC signaling molecules provides a pathway for paracrine and/or autocrine regulation of cellular functions via cGMP in the digestive, renal, central nervous, reproductive, and lymphoid/immune organ systems. Uroguanylin also links the intestine and kidney in a potential endocrine axis that activates tubular receptor-GCs and influences renal function. (Endocrinology 138: 4636 -4648, 1997) 
G UANYLIN and uroguanylin are endogenous peptides
that are similar to the heat-stable toxin (ST) peptides secreted by strains of enteric bacteria that cause secretory (traveler's) diarrhea (1, 2) . This family of small, cysteine-rich peptides activates membrane receptors that contain a guanylate cyclase (GC) catalytic domain within the cytoplasmic portion of the protein (3) . One uroguanylin/guanylin receptor-GC, GC-C, has been identified by molecular cloning of complementary DNAs (cDNAs) from intestinal cDNA libraries (4, 5) . This cell surface receptor-GC belongs to an emerging family of signaling molecules, including the receptors for atriopeptins (3) . GC-C is unique because this protein is localized to apical plasma membranes of cells in the intestinal mucosa, renal tubules, and other epithelia (6 -9) . Localization of receptor-GCs on the mucosal surface of epithelial cells implies that regulation of GC activity occurs via paracrine and/or autocrine mechanisms. The binding of uroguanylin, guanylin, or ST to GC-C enhances the production and intracellular accumulation of cGMP, which in the intestinal epithelium results in stimulation of transepithelial chloride and bicarbonate secretion into the intestinal lumen (1, 2, 10 -12) . A molecular target for cGMP-stimulated protein kinases is the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which may regulate the activity of other anion channels and/or serve to conduct chloride and/or bicarbonate through the apical plasma membrane of enterocytes (13) .
Guanylin was purified from rat jejunum as a small, heatstable peptide that stimulates cGMP accumulation in T84 human intestinal cells (1) . Preproguanylin cDNAs were then isolated, demonstrating that the precursor molecule is a protein of 115-116 amino acids in the rat, human, and mouse intestine (14 -17) . Guanylin messenger RNAs (mRNAs) are more abundant in the large intestine than in the small intestine in rats and humans (14, 15) . Immunoreactive guanylin has been localized to several cell types, including goblet cells, absorptive enterocytes, and enterochromaffin cells (18 -21) . Lower levels of guanylin mRNA were also detected by Northern analyses in RNA preparations obtained from adrenal gland, kidney, and uterus/oviduct of rats (21) . Guanylin and proguanylin were isolated from the hemodialysates of patients with chronic renal failure, indicating that this peptide is secreted into the circulation in patients with this disease (22, 23) . Proguanylin and/or guanylin have not been isolated and identified at the molecular level from the plasma of normal animals or human subjects (24) . Therefore, it is unclear whether guanylin is a circulating peptide hormone under normal physiological conditions.
Uroguanylin was initially isolated from the urine of opossums, and the primary structure was elucidated by N-terminal sequence and mass spectrometry analyses applied to the 13-, 14-, and 15-residue forms of the bioactive peptides (2) . Subsequently, uroguanylin was isolated from human (25) and rat urine (26) , and both uroguanylin and prouroguanylin were purified from the opossum intestine (27, 28) . Complementary DNAs encoding the opossum (24) and human (29, 30) forms of preprouroguanylin were recently isolated that encode 109-and 112-amino acid preprouroguanylin polypeptides, respectively. Northern analyses demonstrated that both uroguanylin and guanylin mRNAs occur throughout the small and large intestines of opossums (24) . Uroguanylin mRNAs are most abundant in the cecum and colon, whereas guanylin mRNAs are highest in the jejunum and ileum of this species. In addition, uroguanylin (but not guanylin) mRNA transcripts were detected in RNA from atria and ventricles of the heart. In rats, uroguanylin mRNAs are greatest in the small intestine, and guanylin mRNAs are most abundant in the large intestine (9, 14, 31 ). An active form of uroguanylin and the inactive prouroguanylin precursor were both isolated from plasma, revealing that uroguanylin is a circulating peptide in normal animals (24) . In patients with chronic renal failure, the plasma levels of uroguanylin increase substantially, indicating that the kidney may clear uroguanylin from the circulation (32, 33) . An endocrine link between intestine and kidney was proposed for uroguanylin acting in vivo to regulate kidney function (34) . Recent demonstrations of the natriuretic, kaliuretic, and diuretic activities of uroguanylin in both the opossum in vivo and in perfused kidneys of the rat in vitro are important elements contributing to the hypothesis that uroguanylin influences salt and water homeostasis as an intestinal natriuretic hormone (35, 36) .
Consistent with the expression pattern for guanylin and uroguanylin mRNAs, the receptor-GC signaling molecules for these peptide agonists are also found on enterocytes lining the intestine. Receptors for uroguanylin, guanylin, and bacterial ST peptides were identified previously through application of several biochemical techniques, including [ 125 I]ST receptor autoradiography in situ, cGMP accumulation responses in vitro and in vivo to the agonist peptides, as well as Northern and in situ hybridization histochemistry analyses detecting GC-C mRNA in the stomach and intestine (6 -9, 19) . In vitro receptor autoradiography and cGMP bioassays demonstrated that receptor-GCs also occur in proximal tubules of the kidney, hepatocytes of liver, seminiferous tubules of testis, and epithelial cells lining the gall bladder, bile duct, and trachea of opossums (7, 8, 37) . Subsequently, Northern analyses and reverse transcription (RT)-PCR amplification methods detected GC-C mRNA in the stomach, adrenal gland, brain, perinatal liver, placenta, and testis of rats and in the human and bovine airway epithelia (9, 21, 38) . The intestinal receptor-GCs are thought to be activated by intraluminally secreted guanylin and/or uroguanylin as first messengers in paracrine and/or autocrine signaling pathways (34) . Such a mechanism is supported by the demonstration that both guanylin and uroguanylin accumulate in solutions perfused through the lumen of the small intestine of rats in vivo (39) . Regulation of receptor-GCs by guanylin and uroguanylin in the kidney may occur via circulating uroguanylin and prouroguanylin entering the tubules by glomerular filtration. Also, uroguanylin and/or guanylin may be produced in tubular cells and secreted into the filtrate within close proximity to target cells in the nephron in a fashion similar to the intrinsic mechanisms found in the intestine.
In the present study, we report the isolation of cDNAs encoding opossum preproguanylin and the catalytic domain of a receptor-GC expressed in OK cells (GC-OK), transiently express the preproguanylin cDNA in COS-1 cells to assess the bioactivity of proguanylin, compare the biological activities of synthetic preparations of guanylin and uroguanylin in the kidney cortex and OK cells, and compare the expression of guanylin, uroguanylin, and GC-OK mRNAs in tissues within the digestive, renal, central nervous, reproductive, and immune/lymphoid organ systems. Uroguanylin, guanylin, and GC-OK mRNAs are widely expressed in tissues outside the intestinal tract of the opossum. Additional studies were conducted using the duodenum, kidney, testis, spleen, and cerebellum to confirm that the molecular machinery required for this signal transduction pathway occurs in these tissues. Thus, uroguanylin and guanylin may regulate cellular cGMP production in target cells within many tissues and organs of the opossum.
Materials and Methods Animals
Opossums were obtained using Havahart traps (Tomahawk Live Trap, Tomahawk, WI) under a permit from the Missouri Department of Conservation issued to W. J. Krause. Animals were housed in the laboratory animal facility of the Missouri University School of Medicine and used under approved experimental protocols.
Cloning of opossum preproguanylin cDNAs
Complementary DNAs encoding preproguanylin were produced using RT of intestinal RNAs to prepare cDNAs followed by rapid amplification of cDNA ends (RACE)-PCR. Total RNA was extracted from opossum colon using the RNeasy kit (Qiagen, Chatworth, CA). The amounts of RNA isolated were measured, and the quality of the RNAs were verified by agarose gel electrophoresis and ethidium bromide staining. Oligo(deoxythymidine) 15 -primed cDNAs were synthesized from 3 g total RNA using reverse transcriptase (Superscript II, Life Technologies, Gaithersburg, MD). Two of the primers used, SHTN-22 [5Ј-GGAGA(TC)TT(TC)TCCTA(TC)CCTCTGG-3Ј] and SHTC-22 [5Ј-GC(AG)AAGGCACAGAT (CT)TCACATG-3Ј] were derived from the N-terminal amino acid sequence (GDFSYPLE) and C-terminal residues (TCEICAFA) of opossum proguanylin, respectively (2, 27) . These oligonucleotide primers generated a 210-bp cDNA product (nucleotides 75-284; Fig. 1A ) when colon cDNA was used as template and 30 cycles of the PCR were carried out at 93 C for 1 min, 58 C for 1 min, and 72 C for 1.5 min using Taq DNA polymerase (U.S. Biochemical Corp., Cleveland, OH). The PCR-generated cDNA products were isolated by electrophoresis using 1% agarose gels, purified (Gel Extraction kit, Qiagen), and ligated into the plasmid vector pCRII (TA Cloning kit, Invitrogen, San Diego, CA), and molecular cDNA clones were sequenced. Automated sequencing was performed by the DNA Core Laboratory of the Missouri University Molecular Biology Program. Two independent clones were sequenced to confirm that the PCR product encoded the expected portion of proguanylin.
To generate the remaining cDNA corresponding to the 3Ј-portion of the preproguanylin mRNA, the 3Ј-RACE-PCR method was used (40) . Briefly, first strand cDNA was made from total RNA of opossum ileum using primers containing deoxythymidine 17 and reverse transcriptase (Life Technologies). The oligonucleotide, 5Ј-GACTCGAGTCGA-CATCGA-3Ј, was attached to the 5Ј-end of the cDNAs during synthesis. These cDNAs were used as template for a PCR reaction with one genespecific oligonucleotide primer corresponding to the guanylin cDNA sequence (5Ј-CCGTGAAGAAACTCAAGGA-3Ј) and an oligonucleotide primer specific for the oligonucleotide attached to the 5Ј-end of the cDNAs. A 580-bp cDNA product was amplified under these conditions, cloned, and sequenced (24) .
A 5Ј-RACE System (Life Technologies) was employed to extend this proguanylin cDNA to synthesize the 5Ј-end of the preproguanylin mRNA. The cDNAs prepared by RT from ileum RNAs were primed with a guanylin-specific oligonucleotide primer, 5Ј-TGGAAAGCCTGGGCT-GCA-3Ј. An anchor homopolymetric dC tail was then added to the 3Ј-end of the cDNA using terminal deoxynucleotidyl transferase and deoxy-CTP. The first round of PCR amplification was carried out using Taq DNA polymerase, an anchor primer provided with the system, 5Ј-CUACUACUACUAGGCCACGCGTCGACTAGTACGGGIIGGGII-GGGIIG-3Ј, and a second guanylin-specific oligonucleotide primer, 5Ј-GGGTGCAGATGGGTTTCAAG-3Ј. Five percent of the PCR mixture was transfered into the second round of PCR. The primers for this PCR were a third guanylin-specific oligonucleotide, 5Ј-GAAGATTCGGGT-GGGCGCAC-3Ј, and a general primer containing the 5Ј-portion of the anchor primer 5Ј-CUACUACUACUAGGCCACGCGTCGAC-TAGTAC-3Ј. The resulting 203-bp cDNA product was cloned by ligation into pCRII and then sequenced. The conditions for both 3Ј-RACE-PCR and 5Ј-RACE-PCR were 30 cycles at 93 C for 1 min, 60 C for 1 min, and 72 C for 1.5 min. At least two independent clones from 5Ј-RACE-PCR and 3Ј-RACE-PCR were sequenced to determine whether PCRinduced errors had occurred in the cDNA sequences.
Expression of preproguanylin in COS-1 cells
The preproguanylin cDNA containing 24 nucleotides of the 5Ј-untranslated region, the 300 nucleotides of open reading frame (ORF), and 41 nucleotides of the 3Ј-untranslated region was generated using RT-PCR from opossum ileum cDNA. This cDNA was ligated into the pCDM8 expression vector at HindIII and XhoI sites (pCDM8-Guan), and the construct was confirmed by sequencing. COS-1 cells cultured in 100-mm dishes were transfected with 3 g pCDM8 vector or pCDM8-FIG. 1. Nucleotide and deduced amino acid sequences for preproguanylin. A, Nucleotides of the preproguanylin cDNA are numbered from 5Ј to 3Ј, starting at the initiation codon, ATG. A consensus polyadenylation signal, AATAAA, is present at nucleotides 641-646. The predicted amino acid sequence for preprouroguanylin is shown below the open reading frame as the single letter abbreviation for each residue. A 20-amino acid hydrophobic signal peptide of preproguanylin is underlined, whereas the double underline denotes the active guanylin peptide isolated from urine and intestinal mucosa (2, 28) . B, Comparison of the primary structures for opossum preproguanylin and preprouroguanylin. Alignment was performed using the GCG program. Identical residues in these proteins are connected with a vertical line, and period symbols indicate deleted residues in preproguanylin that are not found in preprouroguanylin (24) .
Guan using the diethylaminoethyl-dextran procedure (41) . Conditioned medium samples were collected 48 and 72 h after transfection.
For the chymotrypsin pretreatment experiments, the medium samples were heated at 100 C for 30 min in 1 m acetic acid, which has been shown to release the C-terminal guanylin peptide, thus activating the prohormone (27, 28) . The resulting guanylin peptides were isolated from the medium using C 18 Sep-Pak cartridges (octadecylsilane, Waters Associates, Milford, MA) as previously described (2, 27, 28) . The peptides eluting from the C 18 cartridges with 25% acetonitrile-0.1% trifluoroacetic acid (TFA) were dried and reconstituted in 10 mm HEPES, pH 8.0, and then pretreated with 3 g chymotrypsin (Sigma Chemical Co., St. Louis, MO)/100 l or with vehicle as previously described (24, 27, 28) . The subsequent peptide fractions were bioassayed using the cGMP accumulation response to guanylin in cultured human T84 intestinal cells.
The peptides in conditioned medium samples were also extracted with C 18 cartridges without heating the samples at 100 C. Under these conditions, the proguanylin molecule is preserved, whereas heating proguanylin under the conditions described above cleaves this polypeptide to produce the C-terminal guanylin peptide (27) . The polypeptides in conditioned medium from COS-1 cells were eluted from C 18 cartridges first with 25% acteonitrile, 0.1% TFA and then with 50% acetonitrile-0.1% TFA. A portion of these peptide fractions was then bioassayed in T84 cells in the native state, and another aliquot was treated for 30 min at 100 C in 1 m acetic acid. The samples were then bioassayed in T84 cells (1, 2) .
Cloning of the GC-OK cDNA
Total RNA was made from cultured OK cells as described above. Two PCR primers, OK-GC primer (5Ј-GAAACCCTTCCGCCCAGAT-3Ј) and OK-DEG-REV primer (5Ј-CCTCTTCCCTTTAAGTA(CT)GT-3Ј), were designed from regions flanking a highly conserved segment of the rat and human GC-C catalytic domain (4, 5) . A PCR product of the expected size of about 0.9 kilobase (kb) was amplified from the OK cell template cDNA after 30 cycles at 93 C for 1 min, 50 C for 1 min, and 72 C for 2 min using Taq DNA polymerase. The PCR-generated cDNA product was isolated by molecular cloning and sequenced as described above.
RT-PCR analysis of GC-OK mRNAs
Total RNA preparations from opossum tissues were used in cDNA synthesis for RT-PCR amplification of the OK-GC cDNA. The PCR amplification reaction conditions were 30 cycles at 93 C for 1 min, 55 C for 1 min, and 72 C for 1.5 min. The primers were OK51 primer (5Ј-ACAACGAGAGTTACATGGACACC-3Ј) and OK31 primer (5Ј-GGAT-TCCATCCT-TGAGGCTGTG-3Ј), which were expected to amplify a cDNA product of 599 bp. The PCR products were fractionated on 1% agarose gels and visualized with ethidium bromide.
Northern assays of GC-OK mRNAs
Total RNA was prepared as described above, and 20 g of each RNA preparation were subjected to electrophoresis in formaldehyde-agarose gels and then transferred to nylon membranes (MSI, Westboro, MA). The blots were hybridized with the 0.9-kb OK-GC cDNA and ␤-actin cDNA. Prehybridization was performed for 2 h with ExpressHyb (Clontech, Palo Alto, CA) at 68 C, followed by hybridization for 4 h at 68 C, with each cDNA probe labeled by random priming (Boehringer Mannheim, Indianapolis, IN). The blots were washed twice with 2 ϫ SSC (standard saline citrate)-0.1% SDS for 15 min at room temperature. Exposure to x-ray film was performed at Ϫ80 C with intensifying screens.
RT-PCR and Southern analyses
Total RNA was prepared, and first strand cDNAs were synthesized as described above. The PCR primers for uroguanylin corresponding to nucleotides Ϫ21 to Ϫ2 (5Ј-GGAACAAGACTGGCAGACAC-3Ј) and nucleotides 266 -247 (5Ј-GCTCTGAAGATGTTGGCAGC-3Ј) of the opossum preprouroguanylin cDNA sequence were synthesized to amplify a cDNA product of 287 bp (24, 40) . PCR cycles at 93 C for 1 min, 61 C for 1 min, and 72 C for 1.5 min were repeated 35 times. The PCR primers for preproguanylin corresponded to nucleotides 126 -144 (5Ј-CCGT-GAAGAAACTCAAGGA-3Ј) and nucleotides 255-238 (5Ј-TGGAAA-GCCTGGGCTGCA-3Ј) of the opossum preproguanylin cDNA sequence. These oligonucleotides were used to amplify a 130-bp cDNA product. Guanylin PCR conditions were the same as those for uroguanylin PCR, except the annealing temperature was 58 C instead of 61 C. The PCR-generated cDNA products were visualized by agarose gel electrophoresis and ethidium bromide staining. After agarose gel electrophoresis, the cDNAs were transferred to nylon membranes (Bio-Rad, Hercules, CA). The blots were prehybridized for 15 min (QuikHyb, Stratagene, La Jolla, CA) and then hybridized for 1 h at 68 C with 1 ϫ 10 6 cpm/ml 32 P-labeled uroguanylin or guanylin cDNA probes. The blots were washed twice at room temperature, followed by a final wash for 30 min in 0.2 ϫ SSC-0.1% SDS at 60 C.
In vitro receptor autoradiography
Kidney and testis from opossums were frozen with liquid N 2 and stored at Ϫ80 C for sectioning in a cryostat maintained at Ϫ20 C. Adjacent sections were mounted on opposite ends of gelatin-coated slides, which were then stored at Ϫ80 C. Tissue sections were thawed and allowed to dry for 10 min at room temperature before incubation with 50 l DMEM, pH 5.5, and 0.5% BSA at 37 C for 15 min. One section was incubated with this solution plus 1000 cpm [
125 I]ST/l to assess total binding of this radioligand to receptors, whereas the adjacent section was incubated with 1000 cpm [
125 I]ST/l plus 1 m Escherichia coli ST (Sigma Chemical Co.) to assess nonspecific binding, as previously described (8, 9, 37) . After incubation, the sections were initially washed with a stream of cold PBS and then washed three times for 5 min each time in ice-cold PBS. The sections were dried in air and placed in contact with Kodak X-Omat AR x-ray film (Eastman Kodak, Rochester, NY) for initial detection of [
125 I]ST. The slides containing tissue sections were then coated with Kodak NTB-2 emulsion (Eastman Kodak), dried overnight, and sealed in light-tight boxes. The emulsion-coated sections were stored at 4 C for 2-3 weeks until they were developed using standard photographic development and fixation.
Preparation of [ 125 I]ST
E. coli ST was iodinated with 125 I using the Iodogen method (Pierce Chemical Co., Rockford, IL). [
125 I]ST was purified with a C 18 column under reverse phase conditions using HPLC as previously described (7, 8) .
Synthesis of uroguanylin, guanylin, and ST peptides
The opossum uroguanylin (QEDCELCINVACTGC), opossum guanylin (SHTCEICAFAACAGC), and E. coli ST (CCELCCNPACAGC) peptides were synthesized by the solid phase method on an Applied Biosystems model 431A peptide synthesizer (Foster City, CA) and purified by reverse phase C 18 chromatography as previously described (2) .
Cell culture
T84 cells (human colon carcinoma, passage 21, obtained from Dr. James McRoberts, Harbor-University of California-Los Angeles Medical Center, Torrance, CA) were cultured in DMEM and Ham's F-12 medium (1:1) containing 5% FBS, and 60 g penicillin and 100 g streptomycin/ ml, as previously described (1, 2) . Opossum kidney (OK-E) cells were cultured in DMEM and Ham's F-12 medium (1:1) as previously described (7).
cGMP bioassay in opossum kidney slices, OK cells, and T84 cells
OK or T84 cells were cultured in 24-well plastic dishes, and cellular cGMP levels were measured in control and agonist-stimulated cells by RIA (7) (8) (9) . In brief, the synthetic uroguanylin, guanylin, and ST peptides or the recombinant guanylin/proguanylin peptides expressed in COS-1 cells were suspended in 200 l DMEM containing 20 mm HEPES, pH 7.4, and 1 mm isobutylmethylxanthine. T84 or OK cells were washed twice with 200 l DMEM before addition of the peptides. The solutions containing the bioactive peptides were then added to the cultured cells and incubated at 37 C for 40 min. After incubation, the reaction medium was aspirated, and 200 l 3.3% perchloric acid were added/well to stop the reaction and extract cGMP. The extract was adjusted to pH 7.0 with KOH and centrifuged, and 50 l supernatant were used to measure cGMP. Slices of kidney cortex were prepared using a Stadie-Riggs microtome (Thomas Scientific, Swedesboro, NJ) and 50 mg tissue (wet weight) were incubated in 200 l DMEM, HEPES, and isobutylmethylxanthine as described above for the cultured OK and T84 cells and reported previously for kidney slices (7, 8) . The renal slices were incubated for 40 min at 37 C, and the tissue plus medium cGMP were extracted with perchloric acid and measured by RIA.
Results
A cDNA encoding opossum preproguanylin was isolated by molecular cloning with methods that combined RT-PCR to amplify part of the open reading frame of the intestinal mRNA/cDNA for preproguanylin (nucleotides 75-284; Fig.  1A ) coupled with 5Ј-and 3Ј-RACE-PCR to extend this cDNA to include parts of the 5Ј-and 3Ј-untranslated domains of the preproguanylin transcript. The composite cDNA sequence is 688 bp, with an open reading frame encoding a protein of 100 amino acids (Fig. 1A) . The N-terminus of preproguanylin begins with a 20-amino acid hydrophobic signal peptide, which precedes the previously reported N-terminal residues of V 21 TVQDGDFSYPLE 33 for proguanylin that was isolated from opossum intestine (24) . The bioactive guanylin peptides that we isolated from urine and intestinal mucosa (S 86 HTCEICAFAACAGC 100 ) are found at the C-terminus of this protein, followed by a stop codon (2) . Analysis of the preproguanylin structure reveals 40% identity between opossum preproguanylin and preprouroguanylin (Fig. 1B) , indicating that these proteins are related in a family of guanylin-like gene products. Two highly conserved regions between proguanylin and prouroguanylin are at the proguanylin N-terminus represented by L 32 ESVKKLKDL 41 and the C-terminal bioactive peptide, C 89 EICAFAACAGC 100 . Opossum preproguanylin is similar to rat and human preproguanylins, sharing 57% and 60% identity, respectively (14 -17) .
Opossum preproguanylin cDNA molecules were ligated into the eukaryotic expression vector, pCDM8, and transfected into COS-1 cells. Previous experiments demonstrated that the 15-residue guanylin peptide is separated from proguanylin by eluting the adsorbed peptides from C 18 cartridges with 25% acetonitrile to elute guanylin and then with 50% acetonitrile to elute proguanylin (27, 28) . In addition, guanylin is cleaved from proguanylin and activated by heating the prohormone at 100 C in 1 m acetic acid (27) . Guanylin was separated from proguanylin in conditioned medium in these experiments using C 18 chromatography. The peptides eluted with 25% acetonitrile did not stimulate cGMP accumulation in T84 cells when tested before and after heating (data not shown), suggesting that the transfected COS-1 cells did not secrete an active form of guanylin. When the peptides eluted by 50% acetonitrile were bioassayed, we observed that heating this fraction at 100 C in 1 m acetic acid greatly increased its bioactivity in T84 cells (Fig. 2A) . This shows that COS-1 cells transfected with pCDM8-Guan secrete inactive proguanylin into the medium. Another experiment confirmed that the bioactivity was attributed to guanylin by first heating the conditioned medium at 100 C in 1 m acetic acid before isolating guanylin by C 18 chromatography. The bioactivity of this peptide was markedly reduced by pretreatment with chymotrypsin, which inactivates guanylin, thus indicating that proguanylin is secreted from transfected COS-1 cells (Fig. 2B) .
A GC-C-like cDNA was next isolated by PCR cloning using RNA isolated from OK cells to prepare cDNA tem- FIG. 2 . Transfection of the preproguanylin cDNA into COS-1 cells and transient expression produces proguanylin that is secreted into the medium. Conditioned media were collected from COS-1 cells transfected with the plasmid (pCDM8) alone or with a preproguanylin cDNA in the pCDM8 plasmid (pCDM8-Guan) from 48 -72 h after transfection. A, The conditioned media were loaded onto C 18 Sep-Pak cartridges, and the fractions that were eluted with 50% acetonitrile-0.1% TFA were bioassayed using the T84 cell cGMP accumulation response either before or after pretreatment of the eluted samples in 1 M acetic acid at 100 C for 30 min. Also shown is the cGMP accumulation response to 100 nM synthetic opossum guanylin, which was treated with1 M acetic acid at 100 C for 30 min. This is a representative experiment that was repeated at least three times with similar results. B, The conditioned media from control pCDM8 and pCDM8-Guan transfected cells were pretreated at 100 C in 1 M acetic acid before loading medium samples onto C 18 cartridges, followed by elution with 25% acetonitrile-0.1% TFA to isolate guanylin peptides. The eluted samples were pretreated with or without chymotrypsin as described previously (24, 27, 28) and in Materials and Methods. Then the samples were bioassayed using T84 cells as described in A above. This is a representative experiment of at least three such experiments.
plates. Degenerate oligonucleotide primers were synthesized to use in the PCR based on the structure of the catalytic domain of GC-C cDNAs (4, 5) . The cDNA products of the PCR were ligated into the TA cloning vector and transfected into E. coli cells, and an 837-bp GC-OK cDNA was isolated and sequenced. The deduced protein sequence from the cyclase catalytic domain of the GC-OK cDNA is 94.6% and 93.5% identical to human and rat GC-C proteins, respectively (Fig. 3) . This close similarity in the primary structures suggests that the GC-OK protein is an opossum homolog of the GC-C enzyme that is activated by guanylin, uroguanylin, and ST in the intestine and stomach (3) (4) (5) 9) .
Isolation of preproguanylin, preprouroguanylin (24) , and GC-OK cDNAs provided both the structural information and the cDNA probes that are required to investigate the tissue distribution patterns for these signaling molecules. Previously, we reported that uroguanylin mRNAs are expressed in the intestinal mucosa and heart, and that guanylin mRNAs are expressed in the intestine, but not in the myocardium (24) . Transcripts for these peptides were not detected using Northern assays with total RNA preparations from kidney, OK cells, stomach, or liver. To extend this line of investigation, we compared guanylin and uroguanylin mRNA expression in opossum tissues using a more sensitive RT-PCR method coupled with Southern blots using specific cDNA hybridization probes to detect the amplified cDNAs. Figure  4A shows the cDNA products that were produced when RNA samples were prepared and then reverse transcribed to synthesize cDNAs to use as templates for the PCR. In the central nervous system, a uroguanylin cDNA of the expected 287 bp was detected in the cerebellum of brain when the cDNAs on agarose gels were stained with ethidium bromide. In contrast, a guanylin cDNA product of the expected size of 130 bp that was amplified by the RT-PCR was observed throughout these brain regions, including cerebral cortex, cerebellum, hypothalamus, midbrain, medulla, and olfactory bulb, as well as in the spinal cord. For the other organs shown, cDNAs corresponding to mRNAs encoding both guanylin and uroguanylin were observed in stomach, duodenum, kidney, liver, and spleen. We confirmed that only uroguanylin mRNA is expressed in the heart using this RT-PCR method (24) . Moreover, we detected no mRNA expression for either guanylin or uroguanylin in the lung.
To confirm the identity of cDNAs amplified by the PCR, agarose gels containing the cDNAs were blotted to transfer the cDNAs to nylon membranes for hybridization with 32 Plabeled uroguanylin or guanylin cDNAs. Figure 4B shows the hybridization of specific 32 P-labeled cDNAs to the cDNAs that were amplified by RT-PCR using Southern blots of the gels illustrated in Fig. 4A . The guanylin cDNA probe hybridized to guanylin cDNAs, and the uroguanylin cDNA probe hybridized to uroguanylin cDNAs amplified by the PCR. In addition, Southern analyses provided a more sensitive assay to detect the guanylin and/or uroguanylin cDNAs that were amplified by the PCR. Guanylin and uroguanylin cDNA products that were not detected by staining the cDNAs in agarose gels with ethidium bromide (Fig.  4A ) could readily be detected by Southern hybridization analyses, revealing that low levels of uroguanylin mRNA transcripts are present in the midbrain, olfactory bulb, and hypothalamus (Fig. 4B) . Moreover, Southern analyses confirmed that uroguanylin and guanylin mRNA transcripts in the lung are below the detection limit of this assay and that guanylin mRNA is undetectable in the heart. Figure 5 provides a summary of the tissues that were examined for uroguanylin and guanylin mRNA expression by RT-PCR and Southern assays. Each tissue was used to prepare RNA from the listed organs/tissues from at least two different animals for the complete RT-PCR steps to amplify the specific cDNAs. To avoid PCR amplification from genomic DNA, a parallel cDNA synthesis reaction without reverse transcriptase was used as a negative control. No cDNAs were detected under this control condition. Uroguanylin and guanylin mRNAs were found in the small and large intestines, as previously reported using Northern analyses (24) . Other parts of the digestive system, such as salivary glands, pancreas, liver, and gastric mucosa, also express guanylin and uroguanylin mRNAs. In the renal system, we observed that the kidney as well as cultured OK cells and urinary bladder express both guanylin and uroguanylin mRNA transcripts. Uroguanylin and guanylin mRNAs were readily detected by RT-PCR assays using RNA-cDNA from tissues of the immune-lymphoid system, including spleen, thymus, and lymph nodes. In the reproductive organs, guanylin and uroguanylin mRNAs were detected in uterus, ovary, testis, and prostate, whereas guanylin (but not uroguanylin) mRNA was detected in the lactating mammary gland, and neither of these peptide transcripts was observed in the oviduct. The adrenal gland contained mRNAs for both guanylin and uroguanylin, whereas the retina exhibited only uroguanylin mRNA. Thus, guanylin and uroguanylin mRNAs are widely expressed in the opossum.
We concentrated on the duodenum, kidney, cultured OK cells, cerebellum, testis, and spleen to determine whether these tissues and OK cells express mRNAs encoding the molecules required for transmembrane signaling via the uroguanylin/guanylin-GC pathway. In Northern assays, 3.8-kb mRNA transcripts were detected using the GC-OK cDNA probe with total RNA preparations isolated from duodenum, kidney, OK cells, testis, and spleen, but not in RNAs from the cerebellum (Fig. 6) . This is the expected size of GC-C-like mRNA transcripts based on previous reports (4, 5) . In addition to the receptor-GC-OK transcripts, mRNAs for uroguanylin were detected in RNA preparations from duodenum, spleen, and testis (data not shown). Uroguanylin or guanylin mRNA transcripts were not detected by Northern assays using the total RNA preparations made from kidney, OK cells, and cerebellum. RT-PCR assays with primers specific for amplification of the GC-OK catalytic domain amplified a cDNA of the expected size of 0.6 kb when RNAs from duodenum, kidney, OK cells, testis, spleen, and cerebellum were used to prepare the template cDNAs (Fig. 6) . Thus, the receptor-GC-OK mRNA is expressed in all of these tissues in addition to guanylin and/or uroguanylin mRNAs.
The ligand-binding activity of the receptor-GC-OK signaling molecules was assessed in the kidney and testis of the   FIG. 4 . Amplification of guanylin and uroguanylin mRNA-cDNA by RT-PCR using RNA prepared from brain, gastrointestinal tract, kidney, lung, liver, spleen, and heart. A, Uroguanylin and guanylin cDNA products of the expected sizes of 287 and 130 bp, respectively, were amplified by RT-PCR. The cDNAs were resolved on 1% agarose gels by electrophoresis, stained with ethidium bromide, and visualized under UV light. B, The cDNAs on these gels were transferred to Nylon membranes and hybridized with the corresponding uroguanylin or guanylin cDNA probes that were labeled with 32 P. Radioactivity was then detected by autoradiography with x-ray film.
opossum using in vitro receptor autoradiography. [ 125 I]ST was used as the radioligand in binding assays with frozen sections of these tissues. This radioligand binds with high affinity to receptors for uroguanylin and guanylin (8, 9, 37) . Radioactivity, as visualized by silver grains in the photographic emulsion, was localized to epithelial cells within the proximal tubules of kidney and the seminiferous tubules of testis (Fig. 7) . Glomeruli did not bind The enzymatic activity of cell surface GC-OK receptors was assessed by measuring the cellular levels of cGMP using slices of renal cortex and cultured OK cells in vitro. The addition of either synthetic opossum uroguanylin or opossum guanylin elicited a marked increase in the production and accumulation of cGMP in slices of kidney cortex and in confluent monolayers of OK cells (Fig. 8) . These peptides were approximately equipotent in the activation of GC-OK receptors, causing increases in cGMP levels of cultured OK cells elicited by the maximally effective concentrations of peptide agonists. E. coli ST was more potent than the endogenous peptide agonists, as observed previously with T84 intestinal cells (1, 2) . When renal cortical slices were used in this bioassay, we observed that uroguanylin was more potent than guanylin and ST was more potent than either endogenous peptide. In both cultured OK cell and kidney cortex preparations, uroguanylin, guanylin, and ST peptides are full agonists, with parallel concentration-response curves for the activation of apical membrane GC-OK signaling molecules.
Discussion
We report the isolation of cDNAs that encode the opossum form of preproguanylin expressed in the intestine and the catalytic domain of a membrane receptor-GC (i.e. GC-OK) found in the cultured OK cell line. This preproguanylin cDNA produced a precursor of guanylin that was secreted into the medium by COS-1 cells transfected with the preproguanylin cDNA. RT-PCR and Southern assays were used to demonstrate that mRNA transcripts encoding uroguanylin and guanylin precursors are widely expressed in both intestinal and extraintestinal tissues. The mRNAs for the GC-OK receptor for uroguanylin and guanylin were also found in selected tissues of the digestive, renal, central nervous, reproductive, and immune/lymphoid systems. The RNA was prepared, and cDNAs were produced by reverse transcription for each tissue from at least two different animals. ϩ, Positive results observed when the cDNA product was detected in ethidium bromide-stained agarose gels. ϩ*, cDNAs corresponding to uroguanylin and/or guanylin were detected by Southern hybridization analyses, but not with ethidium bromide staining and visualization by UV illumination. -, PCR products were not detectable using RNA from these tissues in the RT-PCR.
FIG. 6. Northern and RT-PCR assays for GC-OK mRNAs.
A, Northern blot assays using 20 g total RNA isolated from duodenum mucosa, OK cells, kidney cortex, spleen, and testis of opossums and probed with the GC-OK cDNA. B, RT-PCR assay for GC-OK mRNA transcripts expressed in the duodenum mucosa, OK cells, kidney cortex, cerebellum-adult, cerebellum-neonatal, spleen, and testis of opossums.
kidney, OK cells, and testis also exhibited receptor activities, as measured using established biochemical methods, including cGMP accumulation responses and/or radioligand binding in vitro (7-9, 37). One conclusion from this study is that uroguanylin and guanylin may regulate cellular functions through paracrine and/or autocrine activation of receptor-GC signaling molecules in many different tissues and organs of the opossum. This animal model and/or cultured OK cells have provided new insights into this uroguanylin/ guanylin-cGMP signaling pathway, which have been subsequently confirmed in other mammalian species (2, 7, 8, 37) . For example, the existence of renal receptors for these agonist peptides (7, 8, 37) and the isolation of uroguanylin from urine (2) were first demonstrated in the opossum before being confirmed in studies with other mammalian species (25, 26, 36) .
The preproguanylin cDNA isolated in this study contains an open reading frame encoding a protein of 100 amino acids, which is shorter than the 115-or 116-amino acid precursors found in the human, rat, and mouse (14 -17) . Opossum preproguanylin is similar in primary structure to the other preproguanylins, sharing 55-60% identity at the amino acid level. The 80-amino acid length of intestinal proguanylin, the N-terminal V 21 TVQDGDFSYPLE 33 peptide domain, and the C-terminal S 86 HTCEICAFAACAGC 100 peptide structure for the bioactive guanylin peptides were identified by N-terminal sequence and mass spectrometry analyses of proguanylin and guanylin molecules previously isolated from opossum intestine (2, 27, 28) . The present experiments confirmed and extended those findings by analysis of the predicted structure of preproguanylin deduced from this cDNA. The 688-bp preproguanylin cDNA isolated in these experiments is close to the approximately 0.8-kb length of preproguanylin mRNAs identified in this study and in previous Northern hybridization assays (24) . The polyadenylase consensus site, AATAAA, occurs at nucleotides 641-646 of this cDNA. Additional nucleotides may be present in the preproguanylin mRNA 5Ј to the 25 nucleotides obtained for the 5Ј-untranslated region.
Prior experiments also revealed that proguanylin made within the intestinal mucosa is inactive unless the protein is cleaved by pretreatment with V8 protease to yield a 16-residue form of guanylin that activates receptor-GC signaling molecules located on the apical surface of T84 cells (27) . Heating the intestinal form of opossum proguanylin at 100 C in 1 m acetic acid also resulted in cleavage of proguanylin to activate the prohormone. The form of proguanylin secreted by transfected COS-1 cells in the present study was also inactive in the T84 cell bioassay until this polypeptide was heated at 100 C in 1 m acetic acid. Moreover, prouroguanylin expressed in COS-1 cells was inactive until a C-terminal form of uroguanylin was released from the precursor by proteolytic cleavage with chymotrypsin (24) . Human and rat forms of proguanylin were also inactive until the C-terminal residues constituting the active guanylin peptides were released by cleavage through the use of proteases or by heating proguanylin in acid (16, 21) . Examination of the highly conserved domains in the opossum proguanylin and prouroguanylin molecules reveal 10 residues near the N-terminus of proguanylin (L 32 ESVKKLKDL 41 ) and prouroguanylin (L 35 DSVKKLDEL 44 ) with similarity of primary structure. Similar homologous domains occur in the human and rat proguanylin and prouroguanylin molecules (14 -16, 29 -31) . This region in the prohormones may function as an inhibitory domain, thus accounting for the inactive nature of proguanylin and prouroguanylin molecules. These highly conserved domains may lie in close proximity to the C-terminal active peptide domain when the precursor proteins are folded in native conformations. An alternate possibility is that these highly conserved domains represent potential bioactive peptides that exert regulatory actions in the intestine or other tissues where proguanylin and/or prouroguanylin are produced, secreted, and cleaved by endogenous proteases.
An experimental model for the paracrine/autocrine regulation of target cell function via intracellular cGMP is found in the intestinal epithelium (reviewed in Ref. 42 ). Proguanylin and prouroguanylin are made in the gastrointestinal mucosa as revealed by this study and previous reports (9, 14 -17, 27-31) . These prohormones are secreted into the intestinal lumen, where they are cleaved and activated by converting enzymes, or posttranslational processing occurs before secretion of the bioactive peptides. Recent experiments have shown that both guanylin and uroguanylin accumulate in luminal perfusates of the small intestine perfused in vivo (39) . These bioactive peptides then interact with and regulate the enzymatic activity of receptor-GC proteins, such as GC-C, that have ligand-binding domains exposed on the mucosal surface of target enterocytes (1, 2, 4 -9) . Increased levels of intracellular cGMP regulates the transepithelial, electrogenic secretion of chloride through cGMPdependent protein kinase-mediated phosphorylation and activation of apical CFTR molecules in target cells within the intestinal mucosa (13, 43, 44) . The potential magnitude of this salt and fluid secretion pathway in the intestine is emphasized by the disorder of traveler's diarrhea, which is caused by bacterial ST peptides that mimic the actions of guanylin and uroguanylin and elicit secretory diarrhea of a remarkable magnitude (6, 10, 42) . Therefore, a major physiological role for guanylin and uroguanylin in the gastrointestinal tract is likely to involve the regulation of salt and water secretion during digestion by an intrinsic cGMP signaling pathway.
Another intestinal transport function that is influenced by these enteric peptides is bicarbonate secretion, which is stimulated by the activation of receptor-GCs in the duodenum (11, 12) . Uroguanylin is probably a major regulator of receptor-GC activity in the duodenum because its mRNA expression in this segment appears greater than that of guanylin mRNA (8, 14, 15, 24, 26, 31) . Also, uroguanylin is a considerably more potent and effective secretogogue than guanylin in stimulating anion secretion when the mucosal surface is exposed to acidic conditions (12, 27, 28, 45) . The contents of the duodenum are acidified during digestion due OK cells cultured in 24-well dishes were treated with the concentrations of synthetic peptides or vehicle shown in this figure for 40 min at 37 C, and then extracts were prepared for measurement of cellular cGMP as previously described (2) . This is a representative experiment that was repeated with similar results.
to entry of the highly acidic chyme from the stomach. In this physiological condition, uroguanylin may stimulate the secretion of bicarbonate from target enterocytes, thus buffering and protecting the mucosal surface from the deleterious effects of mucosal HCl (11, 12) . Such an action of uroguanylin may be particularly important in the portion of the duodenum proximal to the pancreatic duct where duodenal ulcers are commonly found. It should be stressed that uroguanylinstimulated anion secretion in the proximal duodenum is reduced in transgenic animals with impaired CFTR genes, but anion secretion responses to uroguanylin are not completely lost in the duodenum of the CF mouse (12) . This indicates that uroguanylin regulates anion secretion in this segment of the intestine via CFTR-independent as well as CFTR-dependent mechanisms. The transport mechanism(s) responsible for the CFTR-independent secretion of bicarbonate is presently unknown.
A second epithelial tissue that is regulated by uroguanylin and/or guanylin is the kidney, as documented in this and previous studies (7, 8, 37) . Activation of tubular receptor-GCs in the kidney elicits natriuresis, kaliuresis, and diuresis (34 -36) . The local release of uroguanylin and/or guanylin into the filtrate from renal cells that produce these peptides may regulate the transport of sodium and potassium in the nephron via cGMP in a manner similar to that described for the intestinal epithelium. The transporter molecules affected by these peptides via cGMP in the kidney are not known, but cGMP-dependent protein kinase II and CFTR mRNAs are both expressed in the kidney (43, 46, 47) . The cGMP-dependent protein kinase II may be the receptor for intracellular cGMP, with the CFTR protein serving as a target for kinasemediated phosphorylation, leading to the stimulation of chloride secretion and/or an inhibition of sodium reabsorption. These tubular processes could be regulated by the paracrine and/or autocrine actions of locally produced uroguanylin and/or guanylin. Our finding that mRNAs encoding uroguanylin and guanylin are expressed in the opossum kidney are consistent with this postulate. Other observations that mRNAs for these cGMP agonists are found in the rat kidney provide additional evidence of a potential intrarenal signaling pathway (14, 31) . Thus, renal production of uroguanylin and/or guanylin provides agonist peptides for an intrinsic cGMP signal transduction pathway that may regulate renal tubular function in vivo (35, 36 ).
An endocrine pathway may also exist for uroguanylin that links the intestine with the kidney via circulating uroguanylin and prouroguanylin (24, 34) . Prouroguanylin and/or uroguanylin appear to be secreted into the bloodstream, because both prouroguanylin and uroguanylin have been isolated from opossum plasma (24) . The gastrointestinal tract as well as other organs may be sources of plasma uroguanylin and prouroguanylin. These circulating peptides can be filtered at glomeruli to gain access to the receptor-GC signaling molecules that are localized on brush border membranes of renal tubular cells (7, 8, 37) . The diuresis, natriuresis, and kaliuresis elicited by the iv injection of ST into opossums in vivo or perfusion of the isolated rat kidney with uroguanylin or guanylin in vitro are consistent with this hypothesis (35, 36) . Glomerular filtration and renal clearance of circulating uroguanylin and guanylin and their precursors appear to be a major elimination pathway for the circulating peptides as well, because their plasma levels increase dramatically in patients with chronic renal failure (22, 23, 32, 33) . Thus, uroguanylin and/or guanylin may serve in an endocrine axis as natriuretic, kaliuretic, and diuretic peptides. A natriuretic hormone was postulated to exist by Carey and his colleagues, who demonstrated that oral administration of a sodium chloride load caused a much larger natriuresis than did iv administration of the same quantity of salt (48, 49 ). An endocrine model was formulated, consisting of a factor that may be released from the digestive system into the circulation upon the consumption of a high salt meal. Delivery of this natriuretic substance to the kidney via the bloodstream would stimulate urinary salt excretion in times of dietary sodium surfeit. Uroguanylin is a candidate to serve in such an endocrine axis linking the intestine and the kidney to regulate urinary salt excretion during postprandial periods of salt absorption by the digestive tract (34) . In this fashion, uroguanylin could regulate the activity of transmembrane receptor-GC signaling molecules that are expressed in the opossum kidney and localized on the apical surface of renal proximal tubules (7, 8, 37) .
A common theme in the intestine and kidney appears to be the control of salt and water transport by uroguanylin and guanylin. The expression of these peptides and their cognate receptor-GC, GC-OK, in other tissues within the central nervous, reproductive, and immune/lymphoid organ systems suggests that ion transport could also be regulated by this cGMP signaling pathway as a putative physiological mechanism in these tissues. Our findings in the present study confirm previous reports that several extraintestinal epithelia in the opossum express receptors for this class of agonist peptides (7, 8, 37) . The new information presented in this communication extends this cGMP signal transduction pathway to a number of additional tissues in which the molecular machinery potentially exists for an intrinsic mechanism for regulation of target cell function by guanylin-and/or uroguanylin-mediated activation of cell surface receptor-GC enzymes. Signaling via this cGMP pathway in lymphoid tissues is consistent with an earlier description of cGMP accumulation responses to E. coli ST in a cultured basophilic leukemia cell line (50) . Lymphocytes within the spleen, thymus, and lymph nodes of the opossum may express uroguanylin, guanylin, and/or GC-OK mRNA transcripts. These findings suggest that guanylin and/or uroguanylin may influence intracellular cGMP levels in several different tissues within the digestive, renal, central nervous, reproductive, and immune/lymphoid organ systems. The specific cellular targets for the cGMP agonist peptides and the physiological functions influenced by these newly discovered peptides in various organs of the body provide fertile ground for future investigations.
It is possible that unique physiological actions of guanylin and/or uroguanylin may exist in the opossum, Didelphis virginiana, or other marsupials that may not be present in placental mammals. A major difference between eutherian (placental) and metatherian (marsupial) mammals lies in their biology of reproduction. Marsupials have a very short period of intrauterine gestation, and the newborns complete their fetal development attached to mammae, usually in a specialized pouch of the mother. Thus, it is conceivable that the guanylin/uroguanylin signaling pathway could be uniquely functional within the female reproductive organs and/or mammary glands of marsupial mammals. This possibility seems less likely for the cellular functions regulated by the cGMP signaling pathway in the seminiferous tubules of testis. The male opossum is unlikely to have major differences in its reproductive mechanisms from any other mammal, eutherian or metatherian. In other respects, especially in its diet, the opossum is similar to the hominids, placental mammals that evolved as opportunistic hunter/ scavengers with an omnivorous diet. A common ancestor to both placental and marsupial mammals is estimated to have lived during the early Cretaceous period, about 130 million yr before the present time (51) . Recent evidence suggests that the signaling pathway for the guanylin family of peptides appeared much earlier during vertebrate evolution. This conclusion is supported by the recent identification of guanylinlike peptides in the intestine of fish that activate the human receptor-GC found in T84 cells and the correlated demonstration that receptors-GCs exist in the intestinal mucosa of fish that are activated by mammalian guanylin (52) . It is likely that the basic features of this signal transduction pathway emerged quite early in vertebrate evolution and are also highly conserved between fish and man. From this perspective, a reasonable hypothesis may be formulated that predicts that information derived from the opossum will be generally applicable to other mammals, including Homo sapiens.
In conclusion, this study has provided new insights into the potential roles of guanylin and uroguanylin as regulatory peptides for cGMP signaling in several different organs and tissues of the opossum. Both paracrine/autocrine and endocrine signal transduction pathways appear to be involved in the mechanisms of action of uroguanylin and guanylin. Defining both the cellular and organ functions that are regulated by these peptides via intracellular cGMP in the central nervous, reproductive, and immune/lymphoid systems of the body will require additional studies designed to identify the cells within these tissues that produce the agonist peptides and/or express the cell surface receptor-GC signaling molecules. Cellular functions other than the previously documented actions of uroguanylin and guanylin to regulate ion transport in the intestine and kidney should also be considered for these newly discovered peptide hormones.
